Lung transplant patients not given antifungal preventive drugs have higher risk of death: Study

Minnesota [US], September 23 (ANI): Antifungal preventive medications reduce mortality risk by half in the first year following lung transplantation, according to Mayo Clinic research involving 667 patients who received lung transplants from 2005 to 2018.
The retrospective study, published in the Annals of the American Thoracic Society, is the largest ever to evaluate the effectiveness of antifungal preventive drugs in lung transplant recipients who are particularly susceptible to invasive fungal infections. These infections are associated with a nearly threefold increase in mortality for lung transplant recipients.
Mayo Clinic researchers used deidentified administrative claims data from OptumLabs Data Warehouse. The study analysed data for adult patients who underwent a single or double lung transplant, or a concurrent heart-lung transplant, in the US between January 1, 2005, and December 31, 2018. Of the 667 patients, 385, or 57.8 per cent, received antifungal treatment and 282, or 42.3 per cent, did not. Sixty-five patients died during the study, and all-cause mortality was significantly lower in those patients who received antifungal medications.
"Use of antifungal preventive medications in lung transplant patients is increasingly common, but no studies have established its efficacy," says Kelly Pennington, M.D., the study's first author. "This is the first study to demonstrate a mortality benefit associated with the use of antifungal prophylaxis in lung transplant patients. We still do not know which lung transplant patients receive the most benefit from these medications, and there are other unanswered questions that will require more research." Dr Pennington is a Mayo Clinic Scholar in the Division of Pulmonary and Critical Care Medicine.
A 2019 Mayo Clinic study found that 90% of U.S. transplant centres routinely prescribe antifungal preventive medications after lung transplant, but no prospective studies have established the benefits of these medications. "In our retrospective study, the risk of death within the first year posttransplant is about twice as high in patients not receiving antifungal preventive treatment, compared with those receiving treatment," says Dr Pennington.
Itraconazole and voriconazole were the two most common antifungal preventive medications prescribed in the study. Patients who received antifungal drugs had a lower rate of fungal infections than those who did not, though the difference was not statistically significant.
Protracted use of antifungal drugs can have negative health effects, including cardiomyopathy, skin cancer and liver dysfunction. Also, antifungal medications are expensive and can interact with other medications. Therefore, the health care team must monitor anti-fungal medications closely.
"Given the variation in practice among transplant centres, the potential for medication side effects, medication costs and risk of drug interactions, it was imperative to determine whether antifungal preventive medications are beneficial for lung transplant recipients," says Cassie Kennedy, M.D., senior author.
"Our finding of a significant reduction in mortality risk among lung transplant recipients who received antifungal medications is consistent with several prior studies in hematologic malignancies and bone marrow transplant patients." Dr Kennedy is a physician in Mayo Clinic's Division of Pulmonary and Critical Care Medicine. (ANI)